← ANALYST RATINGS · TIPRANKS
Sagimet Biosciences, Inc. Class A (SGMT): analyst forecast and price target
Analyst consensus
Strong Buy11 Buy0 Hold1 Sell
Ratings of 12 analysts in the last 3 months12-month forecast
Based on 12 price targets given in the last 3 months, the average target is $28.46, the highest $56.00, the lowest $7.00. The average is +254.9% from the last price of $8.02.
Analyst ratings 14
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.50 → $8.50+13.3% | Hold | +6.0% | Reiterated | 16.10.26on TipRanks 20:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.50 → $8.50+13.3% | Hold | +6.0% | Reiterated | 16.10.26on TipRanks 20:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 → $8.50+6.2% | Hold | +6.0% | Reiterated | 16.10.26on TipRanks 20:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.50 → $8.50+13.3% | Hold | +6.0% | Reiterated | 16.10.26on TipRanks 20:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 → $8.50+6.2% | Hold | +6.0% | Reiterated | 16.10.26on TipRanks 20:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 → $8.50+13.3% | Hold | +6.0% | Reiterated | 16.10.26on TipRanks 20:05 | — | |
| Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% | H.C. Wainwright | $29.00 | Buy | +261.6% | Reiterated | 05.10.26on TipRanks 06:45 | −1.9%next day −3.5% · 5 days −3.0% | ↗ |
| Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% | Guggenheim | $25.00 → $26.00+4.0% | Buy | +224.2% | Reiterated | 01.10.26on TipRanks Oct 2 06:55 | −5.3%next day −3.2% · 5 days −6.1% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | — | Buy | — | Reiterated | 01.10.26on TipRanks 11:45 | −5.3%next day −3.2% · 5 days −6.1% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $33.00 → $38.00+15.2% | Buy | +373.8% | Reiterated | 01.10.26on TipRanks 07:50 | −5.3%next day −3.2% · 5 days −6.1% | ↗ |
| Yanni Souroutzidis★★★★★★★★★★#10612 · hits 25% · avg −16.7% | Cantor Fitzgerald | $26.40 → $25.10−4.9% | Buy | +213.0% | Reiterated | 01.10.26on TipRanks 07:10 | −5.3%next day −3.2% · 5 days −6.1% | ↗ |
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $56.00 | Buy | +598.3% | Reiterated | 01.10.26on TipRanks 07:10 | −5.3%next day −3.2% · 5 days −6.1% | ↗ |
| Yun Zhong★★★★★★★★★★#12228 · hits 38% · avg −9.6% | Wedbush | $28.00 | Buy | +249.1% | Reiterated | 01.10.26on TipRanks 06:45 | −5.3%next day −3.2% · 5 days −6.1% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | $29.00 → $27.00−6.9% | Buy | +236.7% | Reiterated | 01.10.26on TipRanks 05:50 | −5.3%next day −3.2% · 5 days −6.1% | ↗ |
| Andrea Newkirk★★★★★★★★★★#2841 · hits 50% · avg +29.4% | Goldman Sachs | $7.00 | Sell | −12.7% | Reiterated | 30.09.26on TipRanks Oct 1 09:45 | +6.1%next day −5.3% · 5 days −12.0% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $28.00 | Buy | +249.1% | Reiterated | 30.09.26on TipRanks 17:55 | −5.3%next day −3.2% · 5 days −6.1% | ↗ |
| Debanjana Chatterjee★★★★★★★★★★#121 · hits 68% · avg +45.6% | JonesTrading | $31.00 | Buy | +286.5% | Reiterated | 27.09.26on TipRanks Sep 28 00:45 | +8.3%next day −6.0% · 5 days −10.4% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $8.00 → $18.00+125.0% | Buy | +124.4% | Upgrade | 09.09.26on TipRanks 05:10 | +1.9%next day +2.4% · 5 days −2.6% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | $21.00 | Buy | +161.8% | Reiterated | 12.05.26on TipRanks May 13 00:06 | −0.4%next day −1.2% · 5 days −13.9% | ↗ |
| Seema Sheoran★★★★★★★★★★#8280 · hits 33% · avg +0.9% | Rodman & Renshaw | $28.00 | Buy | +249.1% | Initiated | 26.03.26on TipRanks Mar 31 12:05 | +12.4%next day −2.6% · 5 days +2.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Sagimet Biosciences, Inc. Class A
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $28.37 at a price of $9.88 (+187.2%); now: $28.46 at $8.02 (+254.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 25 | 18 | 17 | 11 | 15 | 20 |
| Buy | 1 | 0 | 0 | 0 | 0 | 1 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 2 | 2 |
Earnings and sales forecast
Next report: 12.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.26 (from $-0.34 to $-0.20). Last quarter: $-0.26.
Best top-analyst consensus in the sector · Healthcare
About Sagimet Biosciences, Inc. Class A
- CEO: David Happel
- Employees: 16
- 155 Bovet Road, San Mateo, CA, 94402, US
- www.sagimet.com
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Data from the stock’s TipRanks forecast page, read 59 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗